Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 12/20 | 0.47 |
| ▸ | RAB9A | P51151 | 12/20 | 0.47 |
| ▸ | POLB | P06746 | 6/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 4/20 | 0.45 |
| ▸ | NFKB2 | Q00653 | 4/20 | 0.45 |
| ▸ | RELA | Q04206 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22743434 | 0.94 | NPC1 (0.46) | RAPGEF4NPC1RAB9APOLBSMN1; SMN2 | |
| SCHEMBL13368865 | 0.85 | NPC1 (0.47) | RAPGEF4NPC1RAB9APOLBSMN1; SMN2 | |
| SCHEMBL21098809 | 0.79 | BAZ2B (0.40) | RAPGEF4NPC1RAB9APOLBSMN1; SMN2 | |
| SCHEMBL14432065 | 0.78 | SYK (0.38) | RAPGEF4NPC1RAB9ASMN1; SMN2NFKB1 | |
| SCHEMBL24073936 | 0.78 | AXL (0.43) | NPC1RAB9AL3MBTL1 | |
| SCHEMBL13884321 | 0.78 | RAB9A (0.51) | NPC1RAB9APOLBSMN1; SMN2ALDH1A1 | |
| SCHEMBL4546338 | 0.77 | RAPGEF4 (0.55) | RAPGEF4NPC1RAB9APOLBSMN1; SMN2 | |
| SCHEMBL30558478 | 0.77 | RAPGEF4 (0.55) | RAPGEF4NPC1RAB9APOLBSMN1; SMN2 | |
| SCHEMBL10189501 | 0.77 | ASIC3 (0.50) | ADRA2A | |
| SCHEMBL379238 | 0.76 | RAPGEF4 (0.63) | RAPGEF4NPC1RAB9APOLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11638760-B2 | Pyrrolobenzodiazepine antibody conjugates | MERSANA THERAPEUTICS, INC. (US) | 2023-05-02 | — | — | US | disclosed |
| US-20170369453-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | MERSANA THERAPEUTICS, INC. | 2017-12-28 | — | — | US | disclosed |
| US-9428472-B2 | Methods of treating bacterial infections with 1,2-benzisothiazolinone and isoindolinone derivatives | GEORGETOWN UNIVERSITY (US) | 2016-08-30 | — | — | US | disclosed |
| US-9040715-B2 | 1,2-benzisothiazolinone and isoindolinone derivatives | GEORGETOWN UNIVERSITY (US) | 2015-05-26 | — | — | US | disclosed |
| US-20140296310-A1 | METHODS OF TREATING BACTERIAL INFECTIONS WITH 1,2-BENZISOTHIAZOLINONE AND ISOINDOLINONE DERIVATIVES | GEORGETOWN UNIVERSITY (US) | 2014-10-02 | — | — | US | disclosed |
| US-8487116-B2 | Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBVIE INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-8304406-B2 | Compounds for treating pulmonary hypertension | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-11-06 | — | — | US | disclosed |
| US-8304406-B2 | Compounds for treating pulmonary hypertension | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-11-06 | — | — | US | disclosed |
| US-20120190845-A1 | FUSED COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR | ABBVIE INC. | 2012-07-26 | — | — | US | disclosed |
| US-8071762-B2 | Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBOTT LABORATORIES (US) | 2011-12-06 | — | — | US | disclosed |
| US-7504391-B2 | Selective D1/D5 receptor antagonists for the treatment of obesity and CNS disorders | SCHERING CORPORATION (US) | 2009-03-17 | — | — | US | disclosed |
| US-20090048244-A1 | PYRROLOTRIAZINE COMPOUNDS AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-02-19 | — | — | US | disclosed |
| EP-2017265-A1 | Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | Abbott Laboratories (US) | 2009-01-21 | — | — | EP | disclosed |
| US-20080287676-A1 | FUSED COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR | ABBOTT LABORATORIES (US) | 2008-11-20 | — | — | US | disclosed |
| EP-1658269-B1 | FUSED COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR | ABBOTT LAB (US) | 2008-10-22 | — | — | EP | disclosed |
| US-7375126-B2 | Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBOTT LABORATORIES (US) | 2008-05-20 | — | — | US | disclosed |
| US-7297695-B2 | Pyrrolotriazine compounds as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-11-20 | — | — | US | disclosed |
| EP-1658269-A1 | FUSED COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR | Abbott Laboratories (US) | 2006-05-24 | — | — | EP | disclosed |
| US-20050043351-A1 | Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBVIE INC. | 2005-02-24 | — | — | US | disclosed |
| WO-2004111009-A1 | FUSED COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR | ABBOTT LABORATORIES (US) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287676-A1 | FUSED COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR | ARRB1, TRPV1, TRPV5 | RAPGEF4 1465/4885NPC1 942/4885RAB9A 1056/4885 |
| US-20140296310-A1 | METHODS OF TREATING BACTERIAL INFECTIONS WITH 1,2-BENZISOTHIAZOLINONE AND ISOINDOLINONE DERIVATIVES | VIP, VIL1, BAK1 | RAPGEF4 4473/4885NPC1 1011/4885RAB9A 2885/4885 |
| US-11638760-B2 | Pyrrolobenzodiazepine antibody conjugates | GABRA4, GABRA1, GABRA2 | RAPGEF4 1781/4885NPC1 1463/4885RAB9A 1082/4885 |
| US-20170369453-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | CD79B, CLTB, FCGR3B | RAPGEF4 1985/4885NPC1 1443/4885RAB9A 528/4885 |
| US-20090048244-A1 | PYRROLOTRIAZINE COMPOUNDS AS KINASE INHIBITORS | ERBB2, ERBB4, ERBB3 | RAPGEF4 677/4885NPC1 3053/4885RAB9A 4200/4885 |
| US-20050043351-A1 | Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ARRB1, TRPV1, TRPV5 | RAPGEF4 1457/4885NPC1 871/4885RAB9A 1020/4885 |
| US-20120190845-A1 | FUSED COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR | ARRB1, TRPV1, TRPV5 | RAPGEF4 1465/4885NPC1 942/4885RAB9A 1056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.